Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas

Inclusion Criteria: * Histologically confirmed relapsed or refractory solid tumor or lymphoma including: * Neuroblastoma * Osteosarcoma * Ewing's sarcoma * Rhabdomyosarcoma * Wilms tumor * CNS tumors * Histological verification not required for brainstem tumors * No acute leukemia * Not eligible for higher priority COG phase I/II study * Performance status - Karnofsky 50-100% (over age 10) * Performance status - Lansky 50-100% (age 10 and under) * At least 2 months * Absolute neutrophil count at least 1,000/mm\^3 * Platelet count at least 75,000/mm\^3 (transfusion independent) * Hemoglobin at least 8.0 g/dL (transfusion allowed) * No granulocytopenia, anemia, and/or thrombocytopenia due to bone marrow involvement * Bilirubin no greater than 1.5 times normal * SGPT no greater than 5 times normal * Albumin at least 2 g/dL * Creatinine no greater than 1.5 times normal * Creatinine clearance or radioisotope glomerular filtration rate at least lower limit of normal * Shortening fraction at least 27% by echocardiogram * Ejection fraction at least 50% by MUGA * Stable neurologic deficits within the past 2 weeks for patients with CNS tumors * CNS toxicity less than grade 2 * No active graft-versus-host disease * No active uncontrolled infection or other serious medical condition * No uncontrolled diabetes mellitus * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * At least 7 days since prior biologic therapy and recovered * Prior bone marrow or stem cell transplantation allowed * At least 6 months since prior allogeneic stem cell transplantation * At least 1 week since prior growth factors * No concurrent immunomodulating agents * At least 2 weeks since prior myelosuppressive chemotherapy (4 weeks for nitrosoureas) and recovered * No other concurrent chemotherapy * Concurrent dexamethasone for CNS tumors allowed if on stable dose for at least 2 weeks prior to study * Concurrent corticosteroids allowed only for increased intracranial pressure in patients with CNS tumors * At least 2 weeks since prior local (small port) palliative radiotherapy * At least 6 months since prior radiotherapy to 50% or more of the pelvis * At least 6 months since prior craniospinal radiotherapy * At least 6 weeks since other prior substantial bone marrow radiotherapy * Recovered from prior radiotherapy * No concurrent radiotherapy except localized palliative radiotherapy * No concurrent anticonvulsants